Article Text
Statistics from Altmetric.com
Footnotes
Twitter Nilesh Kumar @tweet2nilesh and Ashish Sharma @Ashrohini.
Contributors AS: conception, analysis, drafting, integrity check, final approval. NP, NK, FB, BDK, AL, CR, UC: drafting, revision, analysis, integrity check.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. UC received grants from the National Institute for Health Research and Novartis.
Competing interests AS—consultant: Novartis India, Allergan Global, Intas India, Bayer India. NP: none. NK: none. FB—consultant: Allergan, Bayer, Boehringer Ingelheim, Fidia Sooft, Hoffmann-La Roche, Novartis, NTC Pharma, Sifi, ThromboGenics, Zeiss. BDK—clinical research: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; consultant: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. AL—consultant: Allergan, Novartis, Roche, Notal Vision, FiorSightsLabs, Beyeonics, Bayer healthcare. CR—consultant: Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Notal, Merck, Shire-Takeda, Adverum, Graybug, Eyepoint; research support: Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Iveric, Adverum. UC received personal fees from Allergan, Bayer, Novartis, and Roche; and is a data safety and monitoring board member for Bayer.
Provenance and peer review Not commissioned; externally peer reviewed.